Biotechnology
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology
Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.
Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer
Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry
Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion
Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration
Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase
Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.
Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies
Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology
Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review
Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology
Velia Therapeutics Closes Operations, Remains Committed to Microprotein Therapeutic Potential
Velia Therapeutics, microproteins, biotechnology, therapeutic potential, company closure
Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories
Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry
Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook
Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.